Original Article

You have full text access to this OnlineOpen article

Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type†‡

  1. Antonio Salar MD1,2,§,*,
  2. Eva Domingo-Domenech MD3,4,
  3. Cristina Estany MD5,
  4. Miguel A. Canales MD6,
  5. Fernando Gallardo MD1,2,
  6. Octavio Servitje MD3,4,
  7. Guadalupe Fraile MD7,
  8. Carlos Montalbán MD7

Article first published online: 11 AUG 2009

DOI: 10.1002/cncr.24605

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5210–5217, 15 November 2009

Additional Information

How to Cite

Salar, A., Domingo-Domenech, E., Estany, C., Canales, M. A., Gallardo, F., Servitje, O., Fraile, G. and Montalbán, C. (2009), Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer, 115: 5210–5217. doi: 10.1002/cncr.24605

Author Information

  1. 1

    Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain

  2. 2

    Department of Dermatology, Hospital Universitari del Mar, Barcelona, Spain

  3. 3

    Department of Clinical Hematology, ICO/Hospital de Bellvitge, L”Hospitalet de Llobregat, Barcelona, Spain

  4. 4

    Department of Dermatology, Institut Català d'Oncologia/Hospital de Bellvitge, L”Hospitalet de Llobregat, Barcelona, Spain

  5. 5

    Department of Hematology, Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain

  6. 6

    Department of Hematology, Hospital La Paz, Madrid, Spain

  7. 7

    Department of Internal Medicine, Ramon y Cajal Hospital, Madrid, Spain

  1. §

    Fax: (011) 34-93-2483343

*Department of Clinical Hematology, Hospital Universitari del Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain

  1. †

    Presented at the 44th Annual Meeting of the American Society for Clinical Oncology, Chicago, Illinois, May 30-June 3, 2008.

  2. ‡

    We thank Marta Pulido, MD, for editing the article and for editorial assistance.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 11 AUG 2009
  3. Manuscript Accepted: 22 JAN 2009
  4. Manuscript Revised: 18 JAN 2009
  5. Manuscript Received: 4 NOV 2008

Funded by

  • Instituto de Salud Carlos III
  • Spanish Ministry of Science and Technology. Grant Number: PI07/0586
  • Institut Municipal de Investigació Médica
  • Hospital del Mar. Grant Number: ASS/2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

References

  • 1
    Isaacson P, Wright DH. Malignant lymphoma of mucosa associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983; 52: 1410-1416.
    Direct Link:
  • 2
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.
  • 3
    Salar A, Fernandez de Sevilla A, Romagosa V, et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases. Eur J Haematol. 1997; 59: 231-237.
  • 4
    Isaacson PG, Muller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 157-160.
  • 5
    Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997; 15: 1624-1630.
  • 6
    Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999; 17: 1254-1258.
  • 7
    Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in 1 third of 158 patients analyzed. Blood. 2000; 95: 802-806.
  • 8
    Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575-577.
  • 9
    Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995; 345: 1591-1594.
  • 10
    Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995; 122: 767-769.
  • 11
    Montalban C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol. 1995; 6: 355-362.
  • 12
    Bozzetti F, Audisio RA, Giardini R, Gennari L. Role of surgery in patients with primary non-Hodgkin's lymphoma of the stomach: an old problem revisited. Br J Surg. 1993; 80: 1101-1106.
    Direct Link:
  • 13
    Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001; 19: 3874-3883.
  • 14
    Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001; 50: 1258-1264.
  • 15
    Gospodarowicz MK, Pintilie M, Tsang R, Patterson B, Bezjak A, Wells W. Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Results Cancer Res. 2000; 156: 108-115.
  • 16
    Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995; 85: 1075-1082.
  • 17
    Portlock CS, Rosenberg SA. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. Cancer. 1976; 37: 1275-1282.
    Direct Link:
  • 18
    Hammel P, Haioun C, Chaumette M, et al. Efficacy of single agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995; 13: 2524-2529.
  • 19
    Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002; 20: 3872-3877.
  • 20
    Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol. 2000; 11: 363-365.
  • 21
    Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003; 14: 1758-1761.
  • 22
    Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol. 2003; 123: 271-277.
    Direct Link:
  • 23
    Martinelli G, Laszlo DFerreri AJM, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005; 23: 1979-1983.
  • 24
    Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa associated lymphoid tissue lymphoma. Oncology. 2003; 65: 306-310.
  • 25
    Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003; 102: 2741-2745.
  • 26
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999; 17: 268-276.
  • 27
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
  • 28
    Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997; 43: 1005-1037.
  • 29
    Ogawa Y, Hotta T, Tobinai K, et al. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol. 2006; 17: 330-333.
  • 30
    Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24: 174-180.
  • 31
    Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with “low grade” non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol. 1999; 17: 1574-1579.
  • 32
    Oscier D, Orchard JA, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol J. 2001; 2: 316-321.
  • 33
    Palazzo L, Roseau G, Ruskone-Fourmestraux A, et al. Endoscopic ultrasonography in the local staging of primary gastric lymphoma. Endoscopy. 1993; 25: 502-508.
  • 34
    Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994; 5: 397-400.
  • 35
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI-sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1253.
  • 36
    Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma [letter]. Gut. 2003; 52: 1656.
  • 37
    Cancer Therapy Evaluation Program, National Cancer Institute. Common Toxicity Criteria. NCI-CTC version 3.0. Bethesda, Md: National Cancer Institute, 1998. Available at: http://ctep.cancer.gov/reporting/CTC-3.html. Accessed August 9, 2006.
  • 38
    Salar A, Bellosillo B, Serrano S, Besses C. Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. J Clin Oncol. 2005; 23: 7361-7362.
  • 39
    Streubel B, Ye H, Du MQ, et al. Translocation t(11;18) (q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology. 2004; 66: 476-480.
  • 40
    Byrd JC, Peterson BL, Morrison VA, et al. Randomised phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 6-14.
  • 41
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833.
  • 42
    Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995; 49: 135-142.
    Direct Link:
View Full Article (HTML) Get PDF (132K)